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Abstract
The deletion 22q13.3 syndrome (deletion 22q13 syndrome or Phelan-McDermid syndrome) is a
chromosome microdeletion syndrome characterized by neonatal hypotonia, global developmental
delay, normal to accelerated growth, absent to severely delayed speech, and minor dysmorphic
features. The deletion occurs with equal frequency in males and females and has been reported in
mosaic and non-mosaic forms. Due to lack of clinical recognition and often insufficient laboratory
testing, the syndrome is under-diagnosed and its true incidence remains unknown. Common
physical traits include long eye lashes, large or unusual ears, relatively large hands, dysplastic
toenails, full brow, dolicocephaly, full cheeks, bulbous nose, and pointed chin. Behavior is autistic-
like with decreased perception of pain and habitual chewing or mouthing. The loss of 22q13.3 can
result from simple deletion, translocation, ring chromosome formation and less common structural
changes affecting the long arm of chromosome 22, specifically the region containing the SHANK3
gene. The diagnosis of deletion 22q13 syndrome should be considered in all cases of hypotonia of
unknown etiology and in individuals with absent speech. Although the deletion can sometimes be
detected by high resolution chromosome analysis, fluorescence in situ hybridization (FISH) or array
comparative genomic hybridization (CGH) is recommended for confirmation. Differential diagnosis
includes syndromes associated with hypotonia, developmental delay, speech delay and/or autistic-
like affect (Prader-Willi, Angelman, Williams, Smith-Magenis, Fragile X, Sotos, FG,
trichorhinophalangeal and velocardiofacial syndromes, autism spectrum disorders, cerebral palsy).
Genetic counseling is recommended and parental laboratory studies should be considered to
identify cryptic rearrangements and detect parental mosaicism. Prenatal diagnosis should be offered
for future pregnancies in those families with inherited rearrangements. Individuals with deletion
22q13 should have routine examinations by the primary care physician as well as genetic evaluations
with referral to specialists if neurological, gastrointestinal, renal, or other systemic problems are
suspected. Affected individuals benefit from early intervention programs, intense occupational and
communication therapies, adaptive exercise and sport programs, and other therapies to strengthen
their muscles and increase their communication skills. No apparent life-threatening organic
abnormalities accompany the diagnosis of deletion 22q13.
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Disease name and synonyms
Deletion 22q13.3 syndrome
Deletion 22q13 syndrome
22q13 deletion syndrome
Phelan-McDermid syndrome
Monosomy 22q13
Definition and diagnostic criteria
The deletion 22q13 syndrome (or Phelan-McDermid syn-
drome) is a microdeletion syndrome characterized by
severe neonatal hypotonia (>97%) and global develop-
mental delay (>98%), normal to accelerated growth
(95%), absent to severely delayed speech (>98%), and
minor dysmorphic features. Although the characteristic
features are non-specific, the concomitant occurrence of
these finding should prompt the clinician to suspect this
diagnosis. The diagnosis is based on cytogenetic, molecu-
lar cytogenetic, and/or molecular demonstration of loss or
disruption of chromosome region 22q13.3 which con-
tains the SHANK3/ProSAP2 gene [1-3].
Epidemiology
The incidence of deletion 22q13 syndrome has not been
determined. The deletion occurs with equal frequency in
males and females and has been reported in mosaic and
non-mosaic forms. The structural abnormalities may be
inherited or de novo. This syndrome is clearly under-diag-
nosed at both the laboratory and the clinical levels. Over
30% of individuals with Phelan-McDermid syndrome
have required two or more chromosome studies to detect
the deletion cytogenetically. Adding FISH (fluorescence in
situ hybridization) and array CGH (comparative genomic
hybridization) to the diagnostic armamentarium have sig-
nificantly enhanced the detection of this deletion. The
analyses of data collected from subtelomeric studies sug-
gest that deletion 22q13 is second to deletion 1p36 as the
most common terminal deletion leading to a clinically
significant chromosomal disorder [4,5].
Clinical description
The clinical characteristics of deletion 22q13 syndrome
are presented in Table 1. At birth, the features of Phelan-
McDermid syndrome are quite subtle. Birth weight is
appropriate for gestational age and physical features are
often unremarkable. Common physical traits include
long eye lashes, large or unusual ears, relatively large
hands, dysplastic toenails, full brow, dolicocephaly, full
cheeks, bulbous nose, and pointed chin. Hypotonia, feed-
ing problems, and developmental delay are often the early
presenting symptoms of deletion 22q13 syndrome. The
presence of neonatal hypotonia may be the only indicator
that genetic studies are warranted. The Phelan-McDermid
syndrome should be considered in all cases of neonatal
hypotonia of unknown etiology.
Table 1: Clinical characteristics of deletion 22q13 syndrome
Occurring in >95%
Severe global developmental delay
Absent/severe speech delay
Hypotonia
Normal/accelerated growth
Occurring in >75%
Long eye lashes
Prominent, dysplastic ears
Relatively large, fleshy hands
Hypoplastic/dysplastic toenails
Decreases sensitivity to pain
Occurring in >50%
Dolicocephaly
Full brow
Prominent/dysplastic ears
Full/puffy cheeks
Full/puffy eyelids
Pointed chin
Deep set eyes
Ptosis
Decreased perspiration/tendency to overheat
Flat midface
Wide nasal bridge
Bulbous nose
Sacral dimple
Occurring in >25%
Cyclic vomiting
Strabismus
Epicanthal folds
Wide spaced teeth/malocclusion
2–3 syndactyly of the toes
Fifth finger clinodactyly
Seizures
Lymphedema
Gastroesophageal reflux
Renal abnormalities
Occurring in <25%
Hearing loss (~20%)
Arachnoid cyst (~15%)
Cellulitis (~10%)
Behavioral features
Poor eye contact
Stereotypic movements
Decreased socialization
Language impairment
Chewing/mouthing of non-food items (80–90%)
Teeth grinding (about 25%)
Tongue thrusting (about 15%)
Aggressive behavior (10–15%)Orphanet Journal of Rare Diseases 2008, 3:14 http://www.ojrd.com/content/3/1/14
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Behavioral features of Phelan-McDermid syndrome
include poor eye contact, stereotypic movements,
decreased socialization, and language impairment con-
sistent with autism spectrum disorders [6-10]. About 3–
6% of autistic individuals have a chromosome abnormal-
ity identified by standard karyotyping. Deletion 22q13
has been shown to be one of the common chromosome
defects associated with autism [4]. The term "syndromic
autism" has been suggested for autism accompanied by
dysmorphic features and the 22q13 deletion syndrome
was cited as an example of a genetic disorder characterized
by autistic behavior [11]. Other specific behavioral char-
acteristics include: chewing/mouthing of non-food items,
teeth grinding, tongue thrusting and aggressive behavior
[10].
Etiology
The Phelan-McDermid syndrome is a microdeletion syn-
drome resulting from loss of 22q13 by simple deletion,
unbalanced translocation, ring chromosome formation,
or other unbalanced structural change [10]. The SHANK3
gene maps to 22q13.3 and codes for a structural protein
found in the post-synaptic density. SHANK3 functions to
connect ion channels and receptors in the post-synaptic
membrane to the cytoskeleton and to signal transduction
pathways. Haploinsufficiency of the SHANK3/PROSAP2
gene is the cause of the major neurological features asso-
ciated with deletion 22q13 [1,3]. The disruption of the
SHANK3/ProSAP2 gene by an apparently balanced rear-
rangement and the alteration of SHANK3 by a frameshift
mutation have also been described as mechanisms lead-
ing to the language deficits and autistic features of Phelan-
McDermid syndrome [2,6].
The size of the deleted region in Phelan-McDermid syn-
drome ranges from 100 kb to over 9 Mb. The minimum
region of overlap is a 90 kb region delineated proximally
by cosmid n66C4 and distally by cosmid n94h12 [12]. A
recurrent breakpoint within a 15 base pair region of the
SHANK3 gene has been identified in three individuals
with Phelan-McDermid syndrome [13].
Diagnostic methods
Chromosome analysis at or above the 550-band level will
detect most deletions of 22q13 although other, more pre-
cise methods are recommended to confirm the deletion.
FISH is often used to confirm the presence of the deletion
and to rule out the presence of a cryptic translocation. The
probe for arylsulfatase A (ARSA) successfully detects the
majority of 22q13.3 deletions. Microdeletions distal to
ARSA may require FISH analysis using the 22q sub-tel-
omere probe [6,14]. If there is a high degree of clinical sus-
picion, FISH for ARSA and the 22q sub-telomere should
be used simultaneously or sequentially. Using a probe set
that targets each of the 41 sub-telomere regions has the
advantage of detecting cryptic translocations that will be
missed if only distal 22q is targeted. Array-based CGH is
more sensitive than FISH and can scan the entire genome
for loss or gain of genetic material [7,13,14]. Array CGH is
capable of detecting unbalanced rearrangements associ-
ated with Phelan-McDermid syndrome by identifying the
loss of genetic material from 22q13 while demonstrating
the gain of material from a second chromosomal region.
While array CGH can identify deletions and unbalanced
translocations, standard karyotyping or FISH is required
to detect balanced rearrangements in parents or other
family members.
Differential diagnosis
The deletion 22q13 syndrome excludes the diagnoses of
chromosomal disorders unrelated to deletion or disrup-
tion of the 22q13 region on the long arm of chromosome
22. Most of the disorders included in the differential diag-
nosis of Phelan-McDermid syndrome are associated with
hypotonia, developmental delay, speech delay and/or
autistic like affect [14].
Prader-Willi syndrome
As with Prader-Willi syndrome, neonatal hypotonia can
be the first presenting symptom of deletion 22q13. Test-
ing for deletion 22q13 should be considered for any child
with a history of neonatal hypotonia of unknown etiol-
ogy.
Angelman syndrome
Many individuals with Phelan-McDermid syndrome have
carried an initial diagnosis of atypical Angelman syn-
drome. Features common to Angelman syndrome and
deletion 22q13 include global developmental delay,
absent speech, ataxic gait, and minor dysmorphic features.
Autism spectrum disorders
The behavioral characteristics of individuals with Phelan-
McDermid syndrome have led to the diagnosis of autism
spectrum disorders. In fact, 22q13 has been described as a
"hot spot" for these disorders [15]. Although autism or
autistic-like behavior is frequently observed in Phelan-
McDermid syndrome, laboratory studies to identify dele-
tion 22q13 can distinguish this syndrome from idiopathic
autism or other types of syndromic autism [7].
Cerebral palsy
Cerebral palsy is a non-specific term for a variety of neu-
rological disorders that are typically present at birth and
affect motor functions. Neonatal hypotonia, poor coordi-
nation, delayed walking and unsteady gait are features
that may lead a clinician to misdiagnose a child with Phe-
lan-McDermid syndrome as having cerebral palsy.Orphanet Journal of Rare Diseases 2008, 3:14 http://www.ojrd.com/content/3/1/14
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Velocardiofacial syndrome (VCF)/22q11.2 deletion 
syndrome
Deletion 22q13 has been fortuitously diagnosed by FISH
in a number of individuals initially tested for VCF. Many
of the commercially available FISH assays for VCF use
ARSA as the control probe. ARSA maps to 22q13 and
therefore detects deletions of this region. Features com-
mon to VCF and Phelan-McDermid syndrome include
hypotonia, broad nasal root, epicanthal folds, narrow
palpebral fissures, renal abnormalities, speech delay, and
developmental delay.
Williams syndrome
Newborns and young children with Williams syndrome
may have hypotonia, puffy eyelids, full cheeks, and global
delay, similar to individuals with Phelan-McDermid syn-
drome. The diagnosis of Williams syndrome can be con-
firmed or excluded by FISH studies targeting the elastin
(ELN) gene at 7q11.2, just as appropriate laboratory stud-
ies can detect deletion 22q13.
Trichorhinophalangeal syndrome (TRP)
Features shared by TRP and Phelan-McDermid syndrome
include hypotonia, bulbous nose, large or prominent ears,
deep set eyes, hypoplastic toenails, and developmental
delay. Microdeletions of 8q24 are associated with TRP.
Smith-Magenis syndrome (SMS)
Hypotonia, speech deficit, delayed motor skills, develop-
mental delay, flat midface, and decreased sensitivity to
pain are features common to Smith-Magenis syndrome
and Phelan-McDermid syndrome. Deletion 17p11.2
which can be detected by chromosome analysis, FISH, or
CGH-arrays confirms the diagnosis of SMS.
Fragile X syndrome
Males with deletion 22q13 who have hypotonia, speech
delay, autistic-like behavior and certain physical features
including large hands, large ears, and tall stature have
been misdiagnosed with fragile X syndrome. The diagno-
sis of fragile syndrome is confirmed by molecular analysis
demonstrating the CGG repeat in the FMR1 gene.
FG syndrome
Features common to FG syndrome and Phelan-McDermid
syndrome are hypotonia, delayed speech, developmental
delay, and autistic-like behavior.
Sotos syndrome
Sotos syndrome is also known as cerebral gigantism and
is characterized by general overgrowth. As in Phelan-
McDermid syndrome, normal birth weight and length,
neonatal hypotonia, poor feeding, motor delay, and
developmental may be seen in Sotos syndrome. Similar
features include dolicocephaly, pointed chin, and large
hands.
Genetic counseling
Targeted laboratory studies are warranted in parents of
individuals with deletion 22q13. The possibility of paren-
tal mosaicism for a simple deletion or structural rear-
rangement that could result in an affected child should be
considered in the laboratory analysis. About 80% of indi-
viduals with Phelan-McDermid syndrome have de novo,
simple deletions of 22q13 [9]. As in other terminal dele-
tion syndromes, the deletion occurs preferentially on the
paternally-derived chromosome 22 [1,3]. Cryptic and
half-cryptic rearrangements have also been identified in
Phelan-McDermid syndrome [10].
About 20% of cases of deletion 22q13 result from unbal-
anced structural rearrangements [1]. Structural abnormal-
ities most commonly associated with deletion 22q13
syndrome are unbalanced translocations and ring chro-
mosomes. The identification of a balanced translocation
involving chromosome 22 in one parent significantly
increases the risk of recurrence in future pregnancies. Sev-
eral families have experienced multiple cases of deletion
22q13 secondary to familial chromosome translocations.
Mother to son transmission of an insertional transloca-
tion has resulted in deletion 22q13 in the son [16].
Recombination of a parental pericentric inversion has
also led to a child with deletion 22q13 [17-19]
Transmission of ring chromosome 22 from parent to off-
spring has been described. In familial cases of ring 22, the
ring chromosome typically results from an end-to-end
fusion of the long and short arms of chromosome 22,
with no apparent loss of genetic material. However, at
least one case of Phelan-McDermid syndrome is known to
result from the transmission of a ring chromosome from
a mosaic mother to the affected child (Phelan, personal
communication).
Antenatal diagnosis
Deletion of 22q13 can be detected in amniotic fluid, cho-
rionic villi, and percutaneous umbilical blood samples. As
in postnatal studies, the deletion is subtle and is often dif-
ficult to detect. If deletion of 22q13 is suspected by
banded chromosome, FISH using a probe specific for
22q13 or CGH micro-array analysis should be performed
to confirm this finding.
Antenatal diagnosis should be offered to parents who
carry structural rearrangements that predispose to dele-
tion of 22q13. Simple deletion of 22q13 has not recurred
in offspring of parents with normal karyotypes. However,
in one case, a phenotypically normal parent with low level
mosaicism (6%) for deletion 22q13 gave birth to affectedOrphanet Journal of Rare Diseases 2008, 3:14 http://www.ojrd.com/content/3/1/14
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siblings (Phelan, unpublished). In the absence of exten-
sive laboratory analysis, low level parental mosaicism
may not be suspected until the birth of a second affected
child.
Management
Individuals with Phelan-McDermid syndrome should
receive routine medical care from their primary physician.
A clinical geneticist should be involved following the ini-
tial diagnosis. Periodic genetic evaluations are warranted
to update parents as more information on this syndrome
becomes available. For symptoms affecting particular
organ systems, specialists should be consulted [10]. A
neurologist should be consulted for hypotonia and sei-
zures. For cyclic vomiting, a neurosurgical consult is
appropriate to address issues related to increased intra-
cranial pressure. Arachnoid cysts occur more frequently in
children with deletion 22q13 than in the general popula-
tion. Individuals with Phelan-McDermid syndrome
should have baseline brain imaging studies upon initial
diagnosis and should be re-evaluated if clinical symptoms
of increased cranial pressure occur. Other neurological
problems include ventriculomegaly and reduced myelina-
tion.
Recurrent ear infections, along with the lack of expressive
language, may lead to concerns about hearing deficits.
Typanostomy tubes may be required to treat recurrent ear
infections. A specialist experienced in testing children
with severe developmental delay and communication def-
icits should evaluate hearing in children with deletion
22q13 syndrome.
Gastroesophageal reflux is generally controlled by medi-
cation. In persistent cases, surgery may be required. Recur-
rent vomiting may require intravenous fluids to prevent
dehydration. Because renal malformations are observed
in over 25% of individuals with Phelan-McDermid, a
renal ultrasound should be obtained upon initial diagno-
sis.
Cardiac, respiratory, immunologic, and other medical
issues should be treated in the same manner as they
would be handled in a typical child.
An occupational therapist, physical therapist and nutri-
tion specialist should evaluate feeding problems and early
motor delays related to hypotonia. A child development
specialist should assess children for autism or autistic-like
features. Medication to reduce hyperactivity and self-stim-
ulatory behavior is helpful in certain children.
Children with Phelan-McDermid syndrome often have
more advanced perceptive language than expressive lan-
guage. Therapies should be directed at improving verbal
and nonverbal communication. Sign language, computer
touch screens, voice based systems, and picture exchange
systems have been used to increase communication skills.
Adaptive sports, music therapy, and sensory integration
increase the child's awareness and often improve their
desire to communicate. Children with deletion 22q13
greatly benefit from aggressive infant stimulation pro-
grams and individual education plans to improve their
motor skills and communication skills.
Prognosis
Individuals with deletion 22q13 typically have no life-
threatening organic malformations. The number of older
adults with this syndrome is small, therefore the potential
for developing life-threatening conditions with age is
unknown. Deletion 22q13 is a life long disability.
Affected individuals may function well in a group home
setting. It is unlikely that individuals could function inde-
pendently without supervision of parents or other caretak-
ers.
Unresolved questions
￿ Frameshift mutation of SHANK3 has been associated
with the neurological deficits in Phelan-McDermid syn-
drome. Gene sequencing studies are needed to identify
additional mutations of SHANK3 and their role in this
disorder.
￿ Although a plausible role for SHANK3 has been deter-
mined, no additional genetic and/or environmental fac-
tors important in the pathogenesis of this syndrome have
been identified.
￿ Previous studies have not shown a strong correlation
between phenotype and deletion size. Larger series of
patients are required to resolve this question.
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